

February 20, 2026

The Honorable Will Carpenter, Chairperson
House Committee on Health and Human Services
300 SW 10th Avenue, Room 112-N
Topeka, Kansas 66612

Dear Representative Carpenter:

SUBJECT: Fiscal Note for HB 2694 by Representative Simmons

In accordance with KSA 75-3715a, the following fiscal note concerning HB 2694 is respectfully submitted to your committee.

HB 2694 would enact the Opioid Patients Right to Know Act. The Act would specify that before issuing an initial prescription of a schedule II controlled substance, or any other opioid pain reliever that is a prescription drug in the course of treatment for acute or chronic pain, a prescriber would be required to discuss with the patient, or the patient's parent if the patient is a minor, the risks associated with the drugs being prescribed. The topics that the prescriber would be required to discuss would include, but not be limited to:


1. The risk of addiction and overdose associated with opioid drugs;
2. The dangers of taking opioid drugs with alcohol, benzodiazepines, and other central nervous system depressants;
3. The reason the prescription is necessary;
4. Alternative treatment that may be available; and
5. The risk associated with the use of the drugs prescribed.

The prescriber would be required to include a note in the patient's medical record that the prescriber has discussed with the patient or the patient's parent the risks of developing a physical or psychological dependence on the schedule II-controlled substance or other opioid to be prescribed and that alternative treatment may be available. The bill's provisions would not apply to a prescription for a patient who is currently in treatment for cancer, receiving hospice care from

a licensed hospice or palliative care, or a resident of a long-term care facility, or to any medications that are being prescribed for use of substance abuse or opioid dependence.

The Board of Pharmacy, the Board of Healing Arts, and the Kansas Department of Health and Environment indicate the bill's enactment would not have a fiscal effect.

Sincerely,

A handwritten signature in black ink, appearing to read "Adam C. Proffitt", with a stylized flourish at the end.

Adam C. Proffitt
Director of the Budget

cc: Alexandra Blasi, Board of Pharmacy
Susan Gile, Board of Healing Arts
Amy Penrod, Department of Health & Environment